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tion< 1.2%). The repetitions of kV,mA,mAs were in normal range (derivation coef-
ficient< 0.01 ). Image resolution was acceptable (1.4-3.1 lp/mm). ConClusions: 
Review of this study I observed following problems such as we use and installed 
the oldest equipments from other countries, those were worked over than 10 years; 
spare parts were not manufactured; not installed software for measurement and 
process of patients and angiographic staff x-ray doses; not having optional units 
for evaluating and fixing image quality; quality control performance is made by 
Nuclear Energy Agency of Mongolia just one time a year; not acceptance of image 
processing, delivering and printing system. Therefore, more important things are 
in this field are development and renovation of equipments.
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health caRe Use & Policy stUdies – consumer Role in health care
PhP1
FactoRs aFFecting the selection oF soRe thRoat lozenge 
oF dRUgstoRe’s cUstomeR at nakoRnPathom mUniciPality, 
nakoRnPathom PRovince, thailand
Kaewpratum Y., Liyeeke W., Taveesiriwet S., Kanchanapornchai S., Maitreemit P.
Silpakorn university, Nakorn Pathom, Thailand
objeCtives: The aim of this research was finding the factors affect the decision of 
customers in drug stores for selecting the sore throat lozenges. Methods: Survey 
research had been conducted since October to November 2012. The data had been 
collected by using questionnaires from 410 buyers age over 15 years who request the 
sore throat lozenges in drugstores for themselves. Results: Most of respondents 
were women (71.46%), aged 15-25 years old (30.49%), hold bachelor degree (40.73%), 
students (25.12%), no monthly income (27.80%) and had no income (27.80%). Most 
of them used to buy modern medicine types of sore throat lozenges (68.78%) more 
than traditional medicine type (21.22%). Their objectives were for reducing sore throat 
(36.35%) follow by reducing throat irritation (23.97%), reducing cough (19.95%) and 
expectorant (9.98%) respectively. Most of them would buy the modern medicine in 
the next time (69.27%). The level of decision making using available factor and infor-
mation factor were in high level, the price factor and product factor were in medium 
level. The relationship between gender and gender and former using on selecting the 
types of sore throat lozenges were statistical significance of 0.05 levels. The factors 
influenced the selection of sore throat lozenges were 1) Place factor (= 4.02±1.81) espe-
cially selecting from availability and convenience was in the high level, 2) Information 
factor (= 3.60±0.33) especially selecting by using their information and receiving the 
information from health professions were in the high level, receiving the information 
from the various medias and the intimate persons were in the medium level. 3) Price 
factor (= 3.44±0.18) especially selecting from appropriateness to severity was in the 
high level. 4) Product factor (= 3.18±0.50) especially selecting from taste was in the 
high level (= 4.02±1.81). ConClusions: The results could be applied by community 
pharmacists in advising the customers for sore throat lozenges selection and the 
manufacturers or marketing managers in producing and distributing their products.
PhP2
assesing the imPact oF Patent loss on oveRall RevenUes and stocks 
PRice oF PhaRmaceUtical comPanies
Furnback W., Wang B.C.M.
Alliance Life Sciences, Somerset, NJ, USA
objeCtives: With the pre-tax R&D cost of bringing a biopharmaceutical product 
to market estimated at $1.2 billion, revenues from blockbuster drugs may need to 
cover the development cost of multiple drugs. We analyzed four major blockbuster 
products that lost patent between 2011 and 2012 and the associated change in 
sales it had on the company. Methods: We identified four major products (ator-
vastatin, clopidogrel, quetiapine, and montelukast) that lost patent protection 
between 2011 and 2012. Then, we retrieved sales data for the drug, total revenue, 
and stock price for the company from Q1 2011 to Q4 2013. Sales data was from IMS 
Health via drugs. com. Total company revenue per quarter was provided by Charles 
Schwab & Co. and historical stock data was taken from Yahoo! Finance. Results: 
During the time the drugs were under patent, they made up an average of 16.8% 
of total revenues per quarter. Total sales for the four drugs were down an average 
of 78.8% by Q4 2013 while total revenues for the companies were only down on 
average 11.9%. Stock prices over the same period increased an average of 72.5%. 
During the time the product had patent protection, the stock prices of those four 
companies increased at an average of 3.7% per quarter, as opposed to the 5.8% 
increase per quarter when the patent expired. During patent protection, aver-
age company revenue grew at an average of 1.52% per quarter; when the patent 
expired, revenue declined at an average of 1.9%. ConClusions: Overall these 
blockbuster drugs do not seem to significantly decrease revenues and do not 
influence stock prices when their patent protection is up. Large pharmaceuticals 
may reinvest profits to bolster their pipelines and find replacements for these 
large-revenue drugs. Investors seem to appropriately price in patent expiration 
into stock prices long before the actual event.
health caRe Use & Policy stUdies – diagnosis Related group
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the PeRFoRmance- volUme limit decReased the dRg Based acUte caRe 
hosPital Financing in hUngaRy
Endrei D.1, Decsi T.1, Gazsó T.1, Ágoston I.1, Csákvári T.2, Kovács G.3, Boncz I.1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István 
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these patients suffered greater pain and lower HRQoL than nociceptive pain patients. 
The more remarkable improvement NP patients showed after treatment highlights 
the importance of appropriate diagnosis and treatment of NP.
systemic disoRdeRs/conditions – Patient-Reported outcomes & Patient 
Preference studies
Psy9
PRicing and maRket access oF oRPhan dRUgs in asia: a comPaRative 
stUdy acRoss gRowth maRkets
Sherwin G.1, Akpinar P.1, Saraf S.1, Li X.2
1ICON Pricing and Market Access, London, UK, 2ICON Commercialisation & Outcomes, London, UK
objeCtives: With the majority of the world’s population and considerably high 
GDP growth rates, Asia represents a significant opportunity for commercialization 
of orphan drugs (OD) for rare diseases. However, despite some countries implement-
ing policy to facilitate this process, funding for ODs remains challenging due to 
conflicting priorities with coverage of essential medicines. We aimed to understand 
the current coverage policies for ODs in China, Taiwan, Singapore and South Korea, 
and evaluate the impact they have on pricing and market access. Methods: We 
conducted secondary research of government legislation in each country to identify 
specific policy and decision making criteria for coverage of ODs and rare diseases. 
We also selected 8 ODs and scored them based on a pre-defined set of access drivers 
(incidence of the disease, severity of the condition, therapeutic alternatives, level of 
innovation, affordability, etc.). Finally, we analyzed the scores to identify any cor-
relation with the pricing and reimbursement status of these drugs in each market, 
and considered the influence of any identified policies on the results. Results: 
National legislation for OD coverage was identified in Taiwan, Singapore and South 
Korea; however, the degree to which policy influences coverage varies considerably 
between countries. Additionally, in the absence of national legislation in China, 
provincial policies do exist, albeit infrequently and with considerable disparity. 
Scores for access drivers were minimally correlated with pricing and reimbursement 
status, however, high scores were not necessarily indicative of positive coverage; 
rather, affordability is the primary driver for access. ConClusions: Our results 
demonstrate that, although there is considerable market opportunity supported 
by variable legislation to facilitate OD coverage, pricing and market access remains 
challenging and is not necessarily related to individual product value. Therefore, 
pharmaceutical companies seeking access for ODs should consider selective pro-
grams, designed to improve affordability and patient access.
Psy10
the socioeconomic costs oF the UndeRtReatment oF Pain
Hopp M.1, Bosse B.1, Dunlop W.2
1Mundipharma Research GmbH & Co. KG, Limburg, Germany, 2Mundipharma International 
Limited, Cambridge, UK
objeCtives: To investigate the scale and socioeconomic cost of untreated/uncon-
trolled chronic pain. Methods: We performed a systematic literature search in 
PubMed to identify studies reporting the economic cost of pain globally and in Asia 
Pacific. Results: Prevalence estimates for chronic pain among adults range from 
2-40% in the US and 12-30% in Europe, with similar rates reported in Hong Kong 
(10.8%) and Singapore (8.7%). Chronic pain is costly not only because it requires 
medical treatment and complicates treatment for other conditions, but because 
it undermines the ability to lead a productive working and social life, placing a 
substantial burden on individuals, employers, health care systems and societies in 
general. Despite the personal and socioeconomic impact of chronic pain, a large pro-
portion of patients remain untreated. A third of chronic pain patients in a European 
survey were currently not treated, while around half of patients with cancer pain 
are undertreated. Poor availability of medications due to cost, licensing, prescribing 
regulations, lack of training for health care workers and cultural factors are causes 
of undertreatment, especially in the developing world. The majority of countries in 
Asia have limited or very limited availability of medicines for moderate to severe 
pain and no national palliative care policies. The costs associated with chronic pain 
in terms of direct health care and indirect costs are huge, estimated at $560-635 
billion annually in the US and as much as € 300 billion in Europe, and representing 
3-10% of gross domestic product. Chronic pain therefore represents an economic 
burden at least as great as priority health conditions such as heart disease, cancer 
and diabetes. ConClusions: A strategic approach is required to counter the unac-
ceptable burden of uncontrolled chronic pain at the national and international level, 
alongside further research and education into effective treatment, management 
and prevention of pain.
Psy11
stUdy oF technical conditions FoR imPRovement oF angiogRaPhic 
image QUality
Myagmarnaran T.1, Oyunaa C.2, Odongua N.3
1School of Nursing, Health Science University of Mongolia, Ulaanabaatar, Mongolia, 2School of 
Nursing, Health Science University of Mongolia, Ulaanbaatar, Mongolia, 3School of Nursing, 
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objeCtives: The purpose of this study was to explore the quality of angiography 
equipment in diagnosis and treatment used in Mongolia, compare the use of angi-
ography in Mongolia to international standards, type and number of angiography 
examinations, radiologist and patient’s health safety from the effects of X-rays, 
and the study the benefits of the quality control tests of X-rays and how they affect 
image quality and other factors. Methods: By experimental method, used an 
ionization chamber and test object for x-ray image quality to assess angiographic 
image quality based on The Mongolian National Standard MNS 5391:2004. A total 
of 5 angiographies were studied. Measurement acceptance of kV assurance, linear-
ity, repetition of kV,mA,mAs, image resolution were not higher 5% from reference 
values. Results: Standard derivation of kV assurance was moderate (St.deriva-
